Medy Tox Stock Price To Sales
| 086900 Stock | KRW 129,100 300.00 0.23% |
Medy Tox fundamentals help investors to digest information that contributes to Medy Tox's financial success or failures. It also enables traders to predict the movement of Medy Stock. The fundamental analysis module provides a way to measure Medy Tox's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medy Tox stock.
Medy |
Medy Tox Company Price To Sales Analysis
Medy Tox's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Medy Tox Price To Sales | 3.96 X |
Most of Medy Tox's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medy Tox is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Medy Tox has a Price To Sales of 3.965 times. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to sales for all Republic of Korea stocks is notably lower than that of the firm.
Medy Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medy Tox's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medy Tox could also be used in its relative valuation, which is a method of valuing Medy Tox by comparing valuation metrics of similar companies.Medy Tox is rated fifth in price to sales category among its peers.
Medy Fundamentals
| Return On Equity | 0.053 | |||
| Return On Asset | 0.0304 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 989.66 B | |||
| Shares Outstanding | 5.44 M | |||
| Shares Owned By Insiders | 26.72 % | |||
| Shares Owned By Institutions | 10.75 % | |||
| Price To Earning | 57.74 X | |||
| Price To Sales | 3.96 X | |||
| Revenue | 184.87 B | |||
| Gross Profit | 105.47 B | |||
| EBITDA | 45.66 B | |||
| Net Income | 94.15 B | |||
| Cash And Equivalents | 71.77 B | |||
| Total Debt | 55.38 B | |||
| Debt To Equity | 32.80 % | |||
| Current Ratio | 1.03 X | |||
| Book Value Per Share | 21,777 X | |||
| Cash Flow From Operations | 19.97 B | |||
| Earnings Per Share | 1,813 X | |||
| Target Price | 156381.0 | |||
| Number Of Employees | 577 | |||
| Beta | 0.76 | |||
| Market Capitalization | 1 T | |||
| Total Asset | 577.7 B | |||
| Retained Earnings | 131.23 B | |||
| Working Capital | 38 B | |||
| Current Asset | 92.22 B | |||
| Current Liabilities | 54.22 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0 % | |||
| Net Asset | 577.7 B |
About Medy Tox Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medy Tox's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medy Tox using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medy Tox based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medy Tox
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.Moving together with Medy Stock
Moving against Medy Stock
The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medy Stock
Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.